一项前瞻性双中心研究中FAP靶向PET/CT显像在乳腺癌患者中的应用:对诊断和临床管理的启示
该前瞻性双中心研究纳入61例女性乳腺癌患者,评估FAP靶向PET/CT([68Ga]Ga-FAPI-46或[18F]FAPI-42)与[18F]FDG PET/CT及标准影像的诊断准确性及临床影响。FAP靶向PET/CT对原发肿瘤敏感性为100%,高于乳腺超声的82%和[18F]FDG的79%,并改变了部分患者的TNM分期和临床管理。
要点
- FAP靶向PET/CT诊断原发乳腺癌敏感性为100%,高于乳腺超声82%和[18F]FDG 79%。
- FAP靶向PET/CT对复发/转移灶的检出率显著高于[18F]FDG,包括局部/区域复发、颈部及腹部淋巴结、骨和肝转移。
- 相比[18F]FDG,FAP靶向PET/CT改变13/59例(22%)TNM分期和9/59例(15%)临床管理;相比标准影像,改变14/59例(24%)分期和11/59例(19%)治疗方案。
核心结论
- FAP靶向PET/CT诊断原发性和转移性乳腺癌优于[18F]FDG,具有更高的放射性示踪剂摄取和肿瘤/本底比值,尤其在原发/复发肿瘤、腹部淋巴结转移、肝和骨转移检测中。
- FAP靶向PET/CT在TNM分期方面优于[18F]FDG和标准影像,可能改善肿瘤分期、复发检测及必要治疗调整的实施。
研究设计与样本
- 前瞻性双中心研究,纳入2020年6月至2024年1月确诊或疑似乳腺癌患者,共61例女性(中位年龄52岁,范围28-82岁)。
- 患者接受FAP靶向PET/CT(示踪剂为[68Ga]Ga-FAPI-46或[18F]FAPI-42)和[18F]FDG PET/CT;所有初治患者均行乳腺超声作为标准影像。
- 23例评估疑似乳腺病变的明确诊断,15例初始分期,23例评估复发检测。
主要发现
- 乳腺超声、[18F]FDG和FAP靶向PET/CT检测原发乳腺肿瘤的敏感性分别为82%、79%和100%。
- FAP靶向PET/CT对复发/转移灶的病灶检出率显著高于[18F]FDG,包括局部和区域复发、颈部淋巴结、腹部淋巴结、骨和肝转移。
- 与[18F]FDG PET/CT相比,FAP靶向PET/CT改变13/59例(22%)的TNM分期/再分期和9/59例(15%)的临床管理。
- 与标准影像相比,FAPI改变14/59例(24%)的TNM分期/再分期和11/59例(19%)的治疗方案。
- FAPI衍生的SUVmax与原发灶和转移灶的受体状态/组织学类型均无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the diagnostic accuracy and clinical impact of fibroblast activation protein (FAP)-targeted PET/CT imaging in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [18F]FDG PET/CT. METHODS: We prospectively analyzed patients with diagnosed or suspected breast cancer who underwent concomitant FAP-targeted PET/CT (radiotracers including either [68Ga]Ga-FAPI-46 or [18F]FAPI-42) and [18F]FDG PET/CT scans from June 2020 to January 2024 at two medical centers. Breast ultrasound (US) imaging was performed in all treatment-naïve patients as SCI. The SUVmax, tumor-to-background ratio (TBR), lesion detection rate, and tumor-node-metastasis (TNM) classifications between FAP-targeted and [18F]FDG PET/CT were evaluated and compared. RESULTS: Sixty-one female patients (median age, 52 y; range, 28-82 y) were included. Among them, 23 patients underwent evaluation for a definitive diagnosis of suspected breast lesions, 15 underwent initial staging, and 23 were evaluated for the detection of recurrence. The sensitivities of breast US, [18F]FDG, and FAP-targeted PET/CT for detecting primary breast tumors were 82%, 79%, and 100%, respectively. Regarding the diagnosis of recurrent/metastatic lesions, the lesion-based detection rate of FAP-targeted PET/CT was significantly higher than that of [18F]FDG, which included local and regional recurrence, neck lymph node (LN), abdomen LN, bone, and liver metastases. Compared with [18F]FDG PET/CT, FAP-targeted PET/CT altered thirteen patients' TNM staging/restaging (13/59, 22%) and nine patients' clinical management (9/59, 15%). Compared to SCI, FAPI changed fourteen patients' TNM staging/re-staging (14/59, 24%) and eleven patients' therapeutic regimens(11/59, 19%). There was no significant association between FAPI-derived SUVmax and receptor status/histologic type in both primary and metastatic lesions. CONCLUSION: FAP-targeted PET/CT was superior to [18F]FDG in diagnosing primary and metastatic breast cancer, with higher radiotracer uptake and TBR, especially in the detection of primary/recurrent tumors, abdominal LN metastases, liver, and bone metastases. FAP-targeted PET/CT is superior to [18F]FDG and SCI in TNM staging and may improve tumor staging, recurrence detection, and implementation of necessary treatment modifications.
引用
- Guo W, Xu W, Meng T, et al. FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management. Eur J Nucl Med Mol Imaging. 2025. PMID: 39883140. doi:10.1007/s00259-025-07108-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。